Lineage Cell Q3 rev $1.2M, net loss $7.1M; OpRegen Phase 2a enrolling

Lineage Cell Therapeutics, Inc.

2023-Q3 EPS reported -$0.10 revenue$6,857,000

Revenue $1.2M, down 60% YoY from $3.0M; net loss $7.1M ($0.04/sh) vs $6.1M ($0.04/sh) prior year.
Cash $41.3M, expected to fund operations into Q1 2025.
OpRegen Phase 2a in GA secondary to AMD enrolling under Genentech; new data showed rapid retinal structural improvements within 3 months in 5 patients.
On track to submit OPC1 IND amendment in Q4 2023 for spinal cord injury DOSED study.
Initiated hypoimmune pluripotent cell line development with Eterna Therapeutics; selected B2M deletion, HLA-E insertion, and third undisclosed edit.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lineage Cell Therapeutics, Inc. reported the three months ended September 30, 2023 results: revenue $1.2 milli.

Period: the three months ended September 30, 2023
Revenue: $1.2 milli
Result: reported results

Exact text from the filing

revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2023 were $1.2 milli

View on SEC.gov

Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.